In this issue of Blood , Parekh and colleagues provide the first evidence that BCL6 uses different corepressor proteins for different functions. BCL6 requires the Mta3 corepressor to control B-cell differentiation, but not to control cell proliferation and survival. BCL6 is tightly linked to the pathogenesis of diffuse large B-cell lymphoma, and this work has implications for the development of therapies that target BCL6 function.